| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
HYTN Cannabis Inc., a wholly owned subsidiary of HYTN Innovations Inc. (CSE:HYTN) has entered into a sales, distribution and marketing agreement with Rose LifeScience Inc., a supplier of cannabis products in Quebec. The agreement provides a path for HYTN to sell its products, through Rose, to la Société québécoise du cannabis and supports the company’s goal of delivering its consistent, natural cannabis products featuring Elevation Technology to every province and territory in Canada.
HYTN notes that it has achieved vendor qualification in all Canadian markets. However, Quebec is a unique market that requires hands on experience and on the ground presence. Jason Broome, HYTN COO, stated, “Quebec is a critical market for HYTN’s cannabis beverages. Our formulations team has created unique products specifically for Quebec and we are proud that HYTN has focused on Quebec’s needs by delivering the only sugar-free maximum allowable dose, rapid onset beverage available to consumers in the province. It is a testament to our formulation, quality and operations teams that we were able to quickly scale from bench top to brite tank to meet demand.”
Pursuant to the agreement, all revenue from orders of HYTN’s cannabis products will flow from the Société québécoise du cannabis through Rose to HYTN. HYTN will then pay Rose a commission for their services. The company filled its first order under the arrangement this month.
Photo by Tim Foster on Unsplash
Related News
HYTN Launches Nano Gummies Offering 'Faster And More Consistent Cannabis Experience'
HYTN Awarded Medical Cannabis Sales License By Health Canada
Posted In: CSE:HYTN
